Story perspectives

Merck's Welireg Fails Key Cancer Trial, FDA Review Pending

4/22/2026

Summary

Story summary

Merck & Co.'s Welireg failed to improve survival as a first-line treatment for advanced clear cell renal cell carcinoma (ccRCC) in the Litespark-012 trial.
The Welireg, Keytruda, and Lenvima combination did not meet the primary endpoints of progression-free survival or overall survival.
Merck & Co.'s application for FDA review remains pending, with a decision expected by October 4, 2026.
The trial's failure does not impact ongoing Litespark studies.

1 of 1

Story summary

Merck & Co.'s Welireg failed to improve survival as a first-line treatment for advanced clear cell renal cell carcinoma (ccRCC) in the Litespark-012 trial.
The Welireg, Keytruda, and Lenvima combination did not meet the primary endpoints of progression-free survival or overall survival.
Merck & Co.'s application for FDA review remains pending, with a decision expected by October 4, 2026.
The trial's failure does not impact ongoing Litespark studies.